賽升藥業(300485.SZ):賽創投資基金以720萬元受讓海晶生物18%的股權
格隆匯8月9日丨賽升藥業(300485.SZ)公佈,近日,公司收到基金管理人賽盈私募的通知,賽創投資基金與蘇州晶雲藥物科技股份有限公司(“晶雲藥物”或“轉讓方”)簽署了《股權轉讓協議》,賽創投資基金以人民幣720萬元受讓晶雲藥物持有的北京海晶生物醫藥科技有限公司(“海晶生物”或“目標公司”)18%的股權。轉讓完成後,賽創投資基金將持有海晶生物180萬元人民幣註冊資本,對應持有海晶生物18%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.